XTL Biopharmaceuticals Ltd. Stock Nasdaq
Equities
XTLB
US98386D3070
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.56 USD | -1.16% | +3.64% | +153.44% |
Mar. 20 | Top Midday Gainers | MT |
Mar. 20 | XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar | MT |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 6.36M |
---|---|---|---|---|---|
Net income 2021 | - | Net income 2022 | -1M | EV / Sales 2021 | - |
Net cash position 2021 | 6.13M | Net cash position 2022 | 3.72M | EV / Sales 2022 | - |
P/E ratio 2021 |
39.2
x | P/E ratio 2022 |
-4.72
x | Employees | 5 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.3% |
1 day | -1.16% | ||
1 week | +3.64% | ||
Current month | -8.90% | ||
1 month | -2.29% | ||
3 months | +189.36% | ||
6 months | +190.91% | ||
Current year | +153.44% |
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Director/Board Member | 56 | 20-01-28 | |
Director/Board Member | 53 | 17-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.56 | -1.16% | 33,017 |
24-04-23 | 2.59 | -2.26% | 7,580 |
24-04-22 | 2.65 | +8.61% | 27,973 |
24-04-19 | 2.44 | 0.00% | 18,314 |
24-04-18 | 2.44 | -1.21% | 11,936 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- XTLB Stock
- XTLB Stock